Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. - Wikidata - wikimedia - TriplyDB

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.

http://www.wikidata.org/entity/Q37846370

about

Atrial fibrillation in heart failure: an innocent bystander?2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials Lone atrial fibrillation: where are we now?Atrial high-rate episodes and stroke prevention.Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants.Statin Therapy for Primary Prevention of Atrial Fibrillation: Guided by CHADS2/CHA2DS2VASc Score.A meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation.Reactive γ-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells.Aspirin use and risk of atrial fibrillation in the Physicians' Health Study.A new mechanism links preamyloid oligomer formation in the myocyte stress response associated with atrial fibrillation.Recent advances in the molecular pathophysiology of atrial fibrillation.Novel pharmacological targets for the rhythm control management of atrial fibrillation.TPEN prevents rapid pacing-induced calcium overload and nitration stress in HL-1 myocytes.Age and CHADS2 Score Predict the Effectiveness of Renin-Angiotensin System Blockers on Primary Prevention of Atrial Fibrillation Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis.Upstream Treatment of Atrial Fibrillation with n-3 Polyunsaturated Fatty Acids: Myth or Reality?The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis Mechanisms of arrhythmias and conduction disorders in older adults.Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study Atrial fibrillation in heart failure: The sword of Damocles revisited.Fibrosis: a key feature of Fabry disease with potential therapeutic implications Atrial Fibrillation, Cognitive Decline And Dementia.Antioxidant therapies for the management of atrial fibrillation.Do Omega-3 Fatty Acids Decrease the Incidence of Atrial Fibrillation?Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation.Atrial fibrillation: mechanisms, therapeutics, and future directions.Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs.Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications.Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation.Loss of proteostatic control as a substrate for atrial fibrillation: a novel target for upstream therapy by heat shock proteins Individualized therapy in patients with atrial fibrillation: new look at atrial fibrillation.Omega-3 in antiarrhythmic therapy : cons position.Clinical update on the management of atrial fibrillation.Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases.Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies.

P2860

Q27010588-8BD1EC6A-5A5A-4618-ADCE-0F01AFD45545 Q27341873-ADE52F97-6615-477F-8C6D-F799E92BC092 Q28067128-979B2E7A-89EE-4C88-9BF5-471167F30218 Q28087109-929D75D6-AD5F-4EED-B949-50734E05131A Q30409016-EE4AEAEE-215D-4778-92EB-8D2BAE31D9BB Q33589724-2E1F0E2D-6695-463C-933D-EE27663354FB Q33721705-79AFB1DB-12A5-4051-BC58-63D7C9541F6C Q33984012-C3A181E3-3F1F-4FF8-84BA-1D1A02741D68 Q34278784-6C1D2DF5-1EF4-43FF-AA5E-7296C070972A Q34995740-1B56A2B5-E049-428A-9428-FEF3FEE0C69D Q35026193-16B43698-660F-4CF4-9E88-DB37CBD3ED5E Q35137541-2EEAE819-1344-42E2-A91F-D68E55823269 Q35142870-4242732A-FEF3-4017-942A-EE036E1525BB Q35489060-949F1D9B-99E9-4903-9AEE-675CDDA3D363 Q35631361-567AE18E-648B-46FF-8553-70B16071F16E Q35764897-C3F2DC47-699B-40B7-A87D-D5DB8C2D6E19 Q35926637-7DF2A83D-61C6-4F64-BB81-17857F89DB49 Q36353636-5056897C-ED5F-4B90-B434-DBA6D9808932 Q36437128-998AC864-4687-4C80-B1BA-765076F96A3D Q36518152-D9B084E7-6E6D-450E-9568-E4C232ECEA56 Q36650575-0DE4B86E-4E74-41AD-A21D-DFB6F32D54BF Q36723709-60C5DFF9-B65C-4188-B7B9-73005F679064 Q36993177-2D40032A-288A-47AF-B05C-204815957AB0 Q37043226-EEB252B9-C948-4022-AB10-9D4772CFE31E Q37113004-C3FCBE20-B364-4187-8D07-9221193CFAB0 Q37183467-14E91CC0-D2AB-4094-A62A-941779CC88E4 Q37339307-C1AAA9B3-C5A8-4A24-9014-F3A65FA73FB4 Q37495794-37169A4A-60FC-4356-A5F8-0DCB26DAE3C7 Q37496128-AAD5A49A-FAAF-4E1B-AEA8-399DE4E61132 Q37590158-86183504-591F-4A98-AE99-04517067EE2B Q37723799-64BC5750-0308-43DF-9ED2-D6FA10B0EC5A Q37868371-F16FE5A7-4C3D-408F-BA2D-F1C9AC6BC70A Q37963121-E51F37C9-1A46-4750-996F-6B82AF1C2A7A Q37975121-AB624959-9EE8-40BA-9B82-2AF4F61EDC9E Q37989142-6C33C568-39F9-457F-B854-E199EFFAAAB6 Q38056112-D879BEB8-D90F-45E2-95C9-53FA41D93F7E Q38083613-2FD03DFF-F1E3-4A98-A3A0-0CC3CC3F5584 Q38095871-FA79551E-F3AF-4990-B918-01A74DE7923A Q38188453-B2FC268C-4921-4A3B-8BB4-919F39CC4A17 Q38234313-6C44A532-C20B-42AC-A2F9-9A6081BCBDFB

P2860

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.

http://www.wikidata.org/entity/Q37846370

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Upstream therapies for managem ...... s. Part I: primary prevention.

@en

Upstream therapies for managem ...... s. Part I: primary prevention.

@nl

type

label

Upstream therapies for managem ...... s. Part I: primary prevention.

@en

Upstream therapies for managem ...... s. Part I: primary prevention.

@nl

prefLabel

Upstream therapies for managem ...... s. Part I: primary prevention.

@en

Upstream therapies for managem ...... s. Part I: primary prevention.

@nl

P1433

Q37846370-C9483E69-6C37-4286-ACB2-10775C5AB6F7

P1476

Q37846370-F9D1ACEB-1330-43F8-9EE2-B6A5DDC204C8

P2093

Q37846370-000A2851-DA43-420C-8B08-884787E5084F

Q37846370-209B9031-A70D-4AD5-9E97-E03FDECB0D0B

Q37846370-4EE4FAA5-48D2-4A91-A8E4-A017826B635C

P2860

Q37846370-0047E2F9-116E-4D53-B41C-0DC0296263D7

Q37846370-00B860A7-FFD8-4D1F-90C5-110560FD35C4

Q37846370-0186F661-3BE1-42C8-A2B0-0EB00F1D5AB0

Q37846370-05CF9F1A-6B02-42F5-8F82-F3C3E546214A

Q37846370-06D68738-B78F-420B-A521-0214C89B0984

Q37846370-0980E630-73B0-4931-B55B-BFF8D345DAC5

Q37846370-09818D8B-60FB-42FD-8621-EB54F85A12C1

Q37846370-0A3B443A-EC99-4CD4-A009-DB0525216AA4

Q37846370-0A9F7757-6F6E-444A-B50D-EF180C35AFA9

Q37846370-0B1F83B9-79F1-4C05-B43E-7C685FE4F32D

P304

Q37846370-5A346478-2E55-41DB-96E0-6A8296CC53A6

P31

Q37846370-6C7CB803-106F-4BC7-B654-C17BFC71F55C

P356

Q37846370-93248962-C520-4B85-A7CC-53CD39DCEB51

P433

Q37846370-7ED3A828-09B6-4FFF-BA39-71D3758B4441

P478

Q37846370-54BD3066-8E56-4D65-8BBB-AE95EEA0B9EA

P50

Q37846370-ED22FC6C-E858-4EFF-82D0-A0EEC5396AE3

P577

Q37846370-BD2D854B-422F-499E-BEA0-78973BBDF8C8

P5875

Q37846370-A0CDB7E7-FC1A-46D6-8643-C511F3390F98

P698

Q37846370-23C080F8-EACC-4B9D-A12E-B693337B382C

P921

Q37846370-2F686BEF-F330-465C-AE3A-BBCC88B736C5

P356

P1433

P1476

Upstream therapies for managem ...... es. Part I: primary prevention

@en

P2093

A John Camm

http://www.w3.org/2001/XMLSchema#string

Antonios Kourliouros

http://www.w3.org/2001/XMLSchema#string

Irene Savelieva

http://www.w3.org/2001/XMLSchema#string

P2860

Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study

Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.

Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study.

Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance.

Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model.

Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery

P304

308-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EUROPACE/EUR002

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Nikolaos Kakouros

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49966642

http://www.w3.org/2001/XMLSchema#string

P698

21345926

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation